Gilead/J&J NDA Could Mean Another Fixed-Dose Regimen For HIV
This article was originally published in The Pink Sheet Daily
The pill combines J&J’s blockbuster protease inhibitor Prezista (duranavir) with Gilead’s boosting agent cobicistat. Currently, Prezista is required to be administered with the boosting agent ritonavir.
You may also be interested in...
With cost concerns already arising, the sponsor says it is working to ensure the drug is covered by state AIDS Drug Assistance Programs.
The two companies hope to repeat their Atripla success story by teaming up to develop a new combination drug for HIV containing Gilead's cobicistat and Bristol's atazanavir.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.